Close Sidebar
Nordic Life Science
Now Reading
Orion’s darolutamide approved for additional prostate cancer indication in China
Search for content, post, videos
Search for content, post, videos

Orion’s darolutamide approved for additional prostate cancer indication in China

March 20, 2023
1006 Views
Orion R and D
The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is already approved in China for the
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

Sana-Alajmovic-Foto-Johan-Lygrell
April 23, 2014

The Swedish high-tech company Nanologica spins off its asset within obesity into a standalone business distributed to the company's shareholders with Sana Alajmovic serving as CEO. According to an announcement the spin-off is done to speed up development of a new medical product for the treatmenAlready a subscriber Login You have…

January 26, 2022

The next phase in the company's strategy towards 2023 is expected to affect around 1,000 positions in the global organization over the next two years. In 2020, LEO Pharma unveiled its strategy towards 2030. The first phase of this process – including the introduction of a new capital Already a subscriber Login You have read…

November 15, 2021

Valo Therapeutics has successfully raised 11 million EUR in an oversubscribed Pre-IPO funding round. The Pre-IPO fund included participation from existing investors, Freeman Road, and new investors, including ASX-listed MMJ Group Holdings. The total raised to date is now over Euro 22 million (aroAlready a subscriber Login You have read…

Fredrik Alpsten
November 22, 2021

Devyser Diagnostics has announced its intention to launch an initial public offering of its shares and to list its shares on Nasdaq First North Premier Growth Market. The offering is expected to consist of both new shares issued by Devyser and of existing shares in the company. Nasdaq has announcAlready…